Drug Information

Drug General Information
Drug ID
D0HV3A
Former ID
DNC011857
Drug Name
FLUMEZAPINE
Drug Type
Small molecular drug
Indication Discovery agent Investigative [533165]
Formula
C17H19FN4S
Canonical SMILES
CC1=CC2=C(NC3=C(C=CC(=C3)F)N=C2S1)N4CCN(CC4)C
InChI
1S/C17H19FN4S/c1-11-9-13-16(22-7-5-21(2)6-8-22)19-15-10-12(18)3-4-14(15)20-17(13)23-11/h3-4,9-10,19H,5-8H2,1-2H3
InChIKey
CABBDKQGQDDPQA-UHFFFAOYSA-N
PubChem Compound ID
43602
Target and Pathway
Target(s) D(4) dopamine receptor Target Info Inhibitor [533515]
D(2) dopamine receptor Target Info Inhibitor [533165]
Dopamine D1 receptor Target Info Inhibitor [533515]
Muscarinic acetylcholine receptor M4 Target Info Inhibitor [533165]
Muscarinic acetylcholine receptor M5 Target Info Inhibitor [533165]
Muscarinic acetylcholine receptor M2 Target Info Inhibitor [533165]
Muscarinic acetylcholine receptor M1 Target Info Inhibitor [533165]
Muscarinic acetylcholine receptor M3 Target Info Inhibitor [533165]
D(3) dopamine receptor Target Info Inhibitor [533515]
D(1B) dopamine receptor Target Info Inhibitor [533515]
KEGG Pathway Neuroactive ligand-receptor interaction
Dopaminergic synapsehsa04015:Rap1 signaling pathway
cAMP signaling pathway
Gap junction
Dopaminergic synapse
Parkinson's disease
Cocaine addiction
Alcoholismhsa04020:Calcium signaling pathway
Amphetamine addiction
Morphine addiction
Alcoholismhsa04080:Neuroactive ligand-receptor interaction
Cholinergic synapse
Regulation of actin cytoskeletonhsa04020:Calcium signaling pathway
PI3K-Akt signaling pathway
Regulation of actin cytoskeleton
Insulin secretion
Salivary secretion
Gastric acid secretion
Pancreatic secretionhsa04080:Neuroactive ligand-receptor interaction
Dopaminergic synapsehsa04020:Calcium signaling pathway
PANTHER Pathway Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
Dopamine receptor mediated signaling pathway
Nicotine pharmacodynamics pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
Nicotine pharmacodynamics pathwayP05912:Dopamine receptor mediated signaling pathwayP00003:Alzheimer disease-amyloid secretase pathway
Muscarinic acetylcholine receptor 2 and 4 signaling pathwayP00003:Alzheimer disease-amyloid secretase pathway
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathwayP00003:Alzheimer disease-amyloid secretase pathway
Muscarinic acetylcholine receptor 1 and 3 signaling pathwayP00003:Alzheimer disease-amyloid secretase pathway
Muscarinic acetylcholine receptor 1 and 3 signaling pathwayP05912:Dopamine receptor mediated signaling pathway
PathWhiz Pathway Dopamine Activation of Neurological Reward SystemPW000564:Muscle/Heart ContractionPW000565:Gastric Acid Production
Reactome Dopamine receptors
G alpha (i) signalling eventsR-HSA-390651:Dopamine receptors
G alpha (s) signalling eventsR-HSA-390648:Muscarinic acetylcholine receptors
G alpha (i) signalling eventsR-HSA-390648:Muscarinic acetylcholine receptors
G alpha (q) signalling eventsR-HSA-390648:Muscarinic acetylcholine receptors
Acetylcholine regulates insulin secretion
G alpha (q) signalling eventsR-HSA-390651:Dopamine receptors
G alpha (s) signalling events
WikiPathways Hypothetical Network for Drug Addiction
Monoamine GPCRs
GPCRs, Class A Rhodopsin-like
Genes and (Common) Pathways Underlying Drug Addiction
GPCR ligand binding
GPCR downstream signaling
Nicotine Activity on Dopaminergic Neurons
GPCRs, OtherWP666:Hypothetical Network for Drug Addiction
Nicotine Activity on Dopaminergic NeuronsWP666:Hypothetical Network for Drug Addiction
GPCR downstream signalingWP58:Monoamine GPCRs
Calcium Regulation in the Cardiac Cell
Regulation of Actin Cytoskeleton
Gastrin-CREB signalling pathway via PKC and MAPK
GPCR downstream signalingWP706:SIDS Susceptibility Pathways
GPCRs, OtherWP58:Monoamine GPCRs
Secretion of Hydrochloric Acid in Parietal Cells
Integration of energy metabolism
References
Ref 533165J Med Chem. 1989 Dec;32(12):2573-82.Synthesis and pharmacological evaluation of a series of 4-piperazinylpyrazolo[3,4-b]- and -[4,3-b][1,5]benzodiazepines as potential anxiolytics.
Ref 533165J Med Chem. 1989 Dec;32(12):2573-82.Synthesis and pharmacological evaluation of a series of 4-piperazinylpyrazolo[3,4-b]- and -[4,3-b][1,5]benzodiazepines as potential anxiolytics.
Ref 533515J Med Chem. 1982 Oct;25(10):1133-40.Effects of conformationally restricted 4-piperazinyl-10H-thienobenzodiazepine neuroleptics on central dopaminergic and cholinergic systems.

If you find any error in data or bug in web service, please kindly report it to Dr. Tang and Dr. Mou.